β-Cell replacement as a treatment for type 1 diabetes: an overview of possible cell sources and current axes of research.
To efficiently treat type 1 diabetes, exogenous insulin injections currently represent the main approach to counter chronic hyperglycaemia. Unfortunately, such a therapeutic approach does not allow for perfectly maintained glucose homeostasis and, in time, cardiovascular complications may arise. Therefore, seeking alternative/improved treatments has become a major health concern as an increasing proportion of type 2 diabetes patients also require insulin supplementation. Towards this goal, numerous laboratories have focused their research on β-cell replacement therapies. Herein, we will review the current state of this research area and describe the cell sources that could potentially be used to replenish the depleted β-cell mass in diabetic patients.
['Vieira|A|A|', 'Courtney|M|M|', 'Druelle|N|N|', 'Avolio|F|F|', 'Napolitano|T|T|', 'Hadzic|B|B|', 'Navarro-Sanz|S|S|', 'Ben-Othman|N|N|', 'Collombat|P|P|']
D002454:Cell Differentiation D064987:Cell- and Tissue-Based Therapy D000067470:Cellular Reprogramming Techniques D003922:Diabetes Mellitus, Type 1 D022781:Hepatocytes D000066449:Human Embryonic Stem Cells D006801:Humans D007004:Hypoglycemic Agents D057026:Induced Pluripotent Stem Cells D007328:Insulin D050417:Insulin-Secreting Cells D016381:Islets of Langerhans Transplantation D010179:Pancreas D013234:Stem Cells
β-cells type 1 diabetes stem cells transdifferentiation transplantation